Drug2ways: Reasoning over causal paths in biological networks for drug discovery
暂无分享,去创建一个
Martin Hofmann-Apitius | Sarah Mubeen | Daniel Domingo-Fernández | Daniel Rivas-Barragan | Francesc Guim Bernat
[1] L. Kwong,et al. Efficacy of the combination of MEK and CDK4/6 inhibitors in vitro and in vivo in KRAS mutant colorectal cancer models , 2016, Oncotarget.
[2] Jan Baumbach,et al. From single drug targets to synergistic network pharmacology in ischemic stroke , 2019, Proceedings of the National Academy of Sciences.
[3] Taro Kishi,et al. Combination Therapy with Cholinesterase Inhibitors and Memantine for Alzheimer’s Disease: A Systematic Review and Meta-Analysis , 2014, Alzheimer's & Dementia.
[4] Andrea Rocca,et al. Progress with palbociclib in breast cancer: latest evidence and clinical considerations , 2017, Therapeutic advances in medical oncology.
[5] P. Sanseau,et al. Drug repurposing: progress, challenges and recommendations , 2018, Nature Reviews Drug Discovery.
[6] Benjamin J. Raphael,et al. Network propagation: a universal amplifier of genetic associations , 2017, Nature Reviews Genetics.
[7] Min Yi,et al. CDK4/6 and autophagy inhibitors synergistically induce senescence in Rb positive cytoplasmic cyclin E negative cancers , 2017, Nature Communications.
[8] Emanuel F. Petricoin,et al. The repurposed anthelmintic mebendazole in combination with trametinib suppresses refractory NRASQ61K melanoma , 2017, Oncotarget.
[9] Daniel Blankenberg,et al. Software engineering for scientific big data analysis , 2019, GigaScience.
[10] Marco Roos,et al. Drug prioritization using the semantic properties of a knowledge graph , 2019, Scientific Reports.
[11] Gemma C. Garriga,et al. Randomization Techniques for Graphs , 2009, SDM.
[12] Ping Wang,et al. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non–Small Cell Lung Cancers In Vitro and In Vivo , 2016, Clinical Cancer Research.
[13] Sharon Munn,et al. Adverse outcome pathway networks II: Network analytics , 2018, Environmental toxicology and chemistry.
[14] Charles Auffray,et al. Navigating the disease landscape: knowledge representations for contextualizing molecular signatures , 2018, Briefings Bioinform..
[15] Ewold Verhagen,et al. Nonlinear cavity optomechanics with nanomechanical thermal fluctuations , 2016, Nature Communications.
[16] A. Barabasi,et al. Drug—target network , 2007, Nature Biotechnology.
[17] Sebastian F Salathe,et al. Losartan Rescues Inflammation-Related Mucociliary Dysfunction in Relevant Models of Cystic Fibrosis. , 2020, American journal of respiratory and critical care medicine.
[18] A. Barabasi,et al. Network medicine : a network-based approach to human disease , 2010 .
[19] Ryan Miller,et al. WikiPathways: a multifaceted pathway database bridging metabolomics to other omics research , 2017, Nucleic Acids Res..
[20] Peter A. Flach,et al. Caveats and pitfalls of ROC analysis in clinical microarray research (and how to avoid them) , 2012, Briefings Bioinform..
[21] A. Barabasi,et al. Predicting perturbation patterns from the topology of biological networks , 2018, Proceedings of the National Academy of Sciences.
[22] Aurélien Naldi,et al. Decision Diagrams for the Representation and Analysis of Logical Models of Genetic Networks , 2007, CMSB.
[23] S. Kauffman. Metabolic stability and epigenesis in randomly constructed genetic nets. , 1969, Journal of theoretical biology.
[24] Ruth Nussinov,et al. Structure and dynamics of molecular networks: A novel paradigm of drug discovery. A comprehensive review , 2012, Pharmacology & therapeutics.
[25] Evan O. Paull,et al. Inferring causal molecular networks: empirical assessment through a community-based effort , 2016, Nature Methods.
[26] Aki Vehtari,et al. An additive Gaussian process regression model for interpretable non-parametric analysis of longitudinal data , 2019, Nature Communications.
[27] J. Bajorath,et al. Polypharmacology: challenges and opportunities in drug discovery. , 2014, Journal of medicinal chemistry.
[28] Christian Staudt,et al. NetworKit: A tool suite for large-scale complex network analysis , 2014, Network Science.
[29] Michael R Knowles,et al. AGTR2 absence or antagonism prevents cystic fibrosis pulmonary manifestations. , 2019, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.
[30] Gary D Bader,et al. Pathway enrichment analysis and visualization of omics data using g:Profiler, GSEA, Cytoscape and EnrichmentMap , 2019, Nature Protocols.
[31] Doheon Lee,et al. Annotating activation/inhibition relationships to protein-protein interactions using gene ontology relations , 2018, BMC Systems Biology.
[32] Kara Dolinski,et al. The BioGRID interaction database: 2019 update , 2018, Nucleic Acids Res..
[33] Rafael C. Jimenez,et al. The MIntAct project—IntAct as a common curation platform for 11 molecular interaction databases , 2013, Nucleic Acids Res..
[34] Tong Xi,et al. One-year postoperative skeletal stability of 3D planned bimaxillary osteotomies: maxilla-first versus mandible-first surgery , 2019, Scientific Reports.
[35] Minoru Kanehisa,et al. KEGG: new perspectives on genomes, pathways, diseases and drugs , 2016, Nucleic Acids Res..
[36] Edward R. Dougherty,et al. Probabilistic Boolean networks: a rule-based uncertainty model for gene regulatory networks , 2002, Bioinform..
[37] P. Aloy,et al. Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer. , 2017, Cancer research.
[38] B. Al-Lazikani,et al. Combinatorial drug therapy for cancer in the post-genomic era , 2012, Nature Biotechnology.
[39] Reinhard Schneider,et al. Using graph theory to analyze biological networks , 2011, BioData Mining.
[40] Shih-Heng Yeh,et al. A network flow approach to predict drug targets from microarray data, disease genes and interactome network - case study on prostate cancer , 2012, Journal of Clinical Bioinformatics.
[41] Martin Hofmann-Apitius,et al. PathMe: merging and exploring mechanistic pathway knowledge , 2018, BMC Bioinformatics.
[42] Aric Hagberg,et al. Exploring Network Structure, Dynamics, and Function using NetworkX , 2008, Proceedings of the Python in Science Conference.
[43] A. Barabasi,et al. Network-based in silico drug efficacy screening , 2016, Nature Communications.
[44] S. Friend,et al. A network view of disease and compound screening , 2009, Nature Reviews Drug Discovery.
[45] Corrado Priami,et al. A network-based approach to identify deregulated pathways and drug effects in metabolic syndrome , 2019, Nature Communications.
[46] Byung-Gee Kim,et al. Genome-scale model-driven strain design for dicarboxylic acid production in Yarrowia lipolytica , 2018, BMC Systems Biology.
[47] Albert-László Barabási,et al. Publisher Correction: Network-based prediction of drug combinations , 2019, Nature Communications.
[48] Shinji Takeuchi,et al. Reduced doses of dabrafenib and trametinib combination therapy for BRAF V600E-mutant non-small cell lung cancer prevent rhabdomyolysis and maintain tumor shrinkage: a case report , 2020, BMC Cancer.